58,609 results match your criteria Multiple Myeloma

Carfilzomib-related glomerular and tubular injury in a patient with Multiple Myeloma.

J Nephrol 2022 Jun 28. Epub 2022 Jun 28.

Department of Clinical and Experimental Medicine, Hematology Unit, University of Pisa, Pisa, Italy.

View Article and Full-Text PDF

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.

Nat Commun 2022 Jun 27;13(1):3684. Epub 2022 Jun 27.

Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.

Osteolytic destruction is a hallmark of multiple myeloma, resulting from activation of osteoclast-mediated bone resorption and reduction of osteoblast-mediated bone formation. However, the molecular mechanisms underlying the differentiation and activity of osteoclasts and osteoblasts within a myelomatous microenvironment remain unclear. Here, we demonstrate that the osteocyte-expressed major histocompatibility complex class II transactivator (CIITA) contributes to myeloma-induced bone lesions. Read More

View Article and Full-Text PDF


Int J Infect Dis 2022 Jun 24. Epub 2022 Jun 24.

Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic address:

Objective: To study the clinical features of bacterial meningitis in myeloma patients.

Methods: We analyzed myeloma patients included in a nationwide cohort of patients >16 years old with community-acquired bacterial meningitis in the Netherlands between 2006 and 2018. Subsequently, we reviewed the literature for articles reporting myeloma patients with bacterial meningitis. Read More

View Article and Full-Text PDF

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?

J Clin Oncol 2022 Jun 27:JCO2201040. Epub 2022 Jun 27.

Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.

View Article and Full-Text PDF

Thromboprophylaxis in multiple myeloma.

Leuk Lymphoma 2022 Jun 27:1-9. Epub 2022 Jun 27.

Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Venous thromboembolism (VTE) in multiple myeloma (MM) can be secondary to patient-, disease-, and/or treatment-related factors. The development of VTE may result in significant morbidity with the highest risk during the first year after diagnosis. This clinical review provides an evidence-based summary to guide practicing oncologists in the use of anticoagulation to prevent VTE in multiple myeloma and includes anticoagulation efficacy and adverse effect profile. Read More

View Article and Full-Text PDF

Lucid Dreams Associated with Pregabalin: Implications for Clinical Practice.

J Pain Palliat Care Pharmacother 2022 Jun 27:1-6. Epub 2022 Jun 27.

Meghan F. Haas, DO, FACOI, Jessica Latchman, ARNP, Ann M. Guastella, ARNP, David S. Craig, PharmD, and Young D. Chang, MD, are with theDepartment of Supportive Care, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Here, we describe a case of a patient with multiple myeloma who reported symptoms of lucid dreams. This patient was taking methadone for neoplasm related pain. The patient was also taking pregabalin which was initially started at dosing of 50 mg taken orally three times a day. Read More

View Article and Full-Text PDF

Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.

Front Immunol 2022 9;13:897722. Epub 2022 Jun 9.

Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an inflammatory disorder caused by somatic variants, which are sometimes associated with hematological disorders, including myelodysplastic syndrome (MDS). VEXAS syndrome often overlaps with rheumatic diseases, including relapsing polychondritis. Here, we describe a case of VEXAS syndrome with auricular chondritis and exceptional multiple myeloma (MM). Read More

View Article and Full-Text PDF

Data on the clinical, analytical, and laboratory factors associated with negative anion gaps at an academic medical center.

Data Brief 2022 Aug 6;43:108357. Epub 2022 Jun 6.

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.

The anion gap is a calculated parameter derived from the difference between the major plasma cations and anions in serum/plasma or whole blood, with a widely used simple equation utilizing concentrations of sodium, chloride, and bicarbonate. While there is extensive literature on the clinical significance and causes of elevated anion gaps, there is comparatively less data on low anion gaps. Occasionally, anion gap calculations result in a negative number (-1 or less). Read More

View Article and Full-Text PDF

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Front Cell Dev Biol 2022 8;10:879057. Epub 2022 Jun 8.

Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Read More

View Article and Full-Text PDF

Cross-Sectional and Longitudinal Associations Between the Serum G\lobulin Level, and Renal Impairment and All-Cause Deaths in Chinese Patients With Newly Diagnosed Multiple Myeloma.

Front Oncol 2022 8;12:850961. Epub 2022 Jun 8.

Kidney Disease Center, The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China.

Background: A large number of studies have shown that serum globulin plays an important role in a variety of cancers; However, few studies have identified the association between serum globulin levels and end-stage renal disease (ESRD) and all-cause death in Chinese patients with multiple myeloma (MM).

Methods: A generalized additive model and smooth curve fitting were fitted to assess the cross-sectional relationship between the serum globulin levels and renal impairment (RI) at baseline. Multivariate-adjusted Cox regression models were performed to determine the associations between the baseline serum globulin levels and the onset of all-cause death and ESRD in patients with MM. Read More

View Article and Full-Text PDF

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Front Oncol 2022 8;12:925807. Epub 2022 Jun 8.

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, McGowan Institute for Regenerative Medicine, HCC Research Pavilion, University of Pittsburgh, Pittsburgh, PA, United States.

Multiple myeloma (MM) is an incapacitating hematological malignancy characterized by accumulation of cancerous plasma cells in the bone marrow (BM) and production of an abnormal monoclonal protein (M-protein). The BM microenvironment has a key role in myeloma development by facilitating the growth of the aberrant plasma cells, which eventually interfere with the homeostasis of the bone cells, exacerbating osteolysis and inhibiting osteoblast differentiation. Recent recognition that metabolic reprograming has a major role in tumor growth and adaptation to specific changes in the microenvironmental niche have led to consideration of the role of sphingolipids and the enzymes that control their biosynthesis and degradation as critical mediators of cancer since these bioactive lipids have been directly linked to the control of cell growth, proliferation, and apoptosis, among other cellular functions. Read More

View Article and Full-Text PDF

Impact of Atrial Fibrillation on Inpatient Outcomes Among Hospitalized Patients With Multiple Myeloma.

Cureus 2022 May 23;14(5):e25252. Epub 2022 May 23.

Management, Policy and Community Health, University of Texas Health Science Center at Houston, Houston, USA.

Background Though multiple myeloma (MM) patients have been reported to have the highest risk of atrial fibrillation compared to other cancer patients, studies are lacking on the impact of atrial fibrillation on health outcomes in this population. In this study, we examined the impact of atrial fibrillation on inpatient outcomes among hospitalized patients with MM. Methodology Retrospective cohort analyses were conducted using National Inpatient Sample data from 2016 to 2018. Read More

View Article and Full-Text PDF

A retrospective review of infections and outcomes within 100 days of hematopoietic stem cell transplantation: insights from a new transplant program in the Philippines.

IJID Reg 2022 Jun 20;3:101-105. Epub 2022 Mar 20.

Department of Medicine - Section of Infectious Diseases, The Medical City, Ortigas Avenue, Pasig City, Philippines.

Background: Few hematopoietic stem cell transplantations (HSCT) are performed in lower-middle income countries. Only four institutions in the Philippines are able to perform transplants. This study describes the experience of a newly established program. Read More

View Article and Full-Text PDF

Central Nervous System Involvement of Multiple Myeloma Presenting as Short-lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing: A Case Report.

Neurohospitalist 2022 Jul 22;12(3):544-549. Epub 2022 Apr 22.

Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are part of the trigeminal autonomic cephalalgia (TAC) group of headache disorders. Attacks present with repeated, severe, sharp, stabbing, or throbbing pain. Patients may experience a single attack, recurrent attacks with pain-free interictal periods, or a sawtooth pattern background pain with superimposed stabs. Read More

View Article and Full-Text PDF

Apical lung mass-A rare presentation of multiple myeloma.

Radiol Case Rep 2022 Sep 17;17(9):2951-2955. Epub 2022 Jun 17.

Bronxcare health system.

Multiple myeloma is a neoplastic proliferation of immunoglobulin-producing plasma cells with clinical features resulting from infiltration of plasma cells into bones and other organs. Multiple myeloma manifesting as an apical lung mass is less common and very few cases have been reported. We report the case of a 50-year-old female who presented with an apical lung mass which happened to be multiple myeloma arising from the upper ribs into the lung. Read More

View Article and Full-Text PDF
September 2022

Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma.

Blood Rev 2022 Jun 22:100986. Epub 2022 Jun 22.

Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves within the founding tumor clone. Read More

View Article and Full-Text PDF

Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy.

Am J Ophthalmol 2022 Jun 22. Epub 2022 Jun 22.

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

Purpose: The purpose of this study was to investigate epithelial and neuronal changes in patients with refractory/relapsed multiple myeloma (RRMM) before/during belantamab mafodotin (belamaf) treatment using confocal microscopy.

Design: Retrospective case series.

Methods: RRMM patients underwent best corrected visual acuity (BCVA) testing and slit-lamp examination/photography, followed by corneal confocal microscopy (CCM) to evaluate the epithelium and subbasal nerve plexus (SNP) to measure corneal nerve fiber density (CNFD), -branch density (CNBD), and -fiber length (CNFL) before and during belamaf treatment. Read More

View Article and Full-Text PDF

Granular variant of a histiocytic tumor on the toe of a cat: Case report and literature review.

Vet Clin Pathol 2022 Jun 24. Epub 2022 Jun 24.

Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.

A 16-year-old female spayed domestic shorthaired cat was examined for lameness and a mass on the fourth digit of the right hindlimb. Cytologic examination of an aspirate of the mass revealed large discrete cells admixed with low numbers of well-granulated mast cells. The discrete cells contained single to many variably sized light pink to purple granules in their cytoplasm and had pleomorphic nuclei, with intranuclear cytoplasmic inclusions. Read More

View Article and Full-Text PDF

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis.

Pharmacoecon Open 2022 Jun 24. Epub 2022 Jun 24.

Medizinische Klinik und Poliklinik II des Universitätsklinikums, Zentrum Innere Medizin, Würzburg, Germany.

Objective: This study aimed to analyze the healthcare resource use (HCRU) and associated costs of multiple myeloma (MM) using German claims data.

Methods: Anonymized claims data from one of the largest sickness funds in Germany were analyzed. Costs and HCRU were calculated from the perspective of the statutory health insurance. Read More

View Article and Full-Text PDF

Prognostic Impact of Adiposity in Hematological Malignancies: A Systematic Review and Meta-analysis.

Clin Lymphoma Myeloma Leuk 2022 May 29. Epub 2022 May 29.

Sarah Cannon - Nashville TN.

It has been proposed that direct measurement of adiposity has a greater accuracy as a prognostic factor in various malignancies than anthropometric measures such as BMI. We evaluated the association of visceral and subcutaneous adiposity with outcomes in patients with hematological malignancies with a systematic review and meta-analysis. This systematic review included patients with hematological malignancies who had the analysis of overall mortality and progression-free survival according to their adiposity status. Read More

View Article and Full-Text PDF

Sjögren's syndrome as a cause of both lymphoid interstitial pneumonia and light chain deposition disease in a single patient.

BMJ Case Rep 2022 Jun 24;15(6). Epub 2022 Jun 24.

Department of Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.

A man in his 70s presents with 12 months of progressive dyspnoea, sicca symptoms and Raynaud's phenomenon. Serological testing and tear duct biopsy confirm Sjögren's syndrome (SS). Bilateral nodular-cystic appearances highly suggestive of lymphoid interstitial pneumonia (LIP) are noted on high-resolution computed tomography (HRCT), supported by a 40% lymphocytosis on bronchoalveolar lavage. Read More

View Article and Full-Text PDF

High Dose (Conditioning) Regimens used prior to Autologous Stem Cell Transplantation in Multiple Myeloma.

Transplant Cell Ther 2022 Jun 21. Epub 2022 Jun 21.

Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address:

The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the standard of care in patients who are deemed transplant eligible. Novel therapies, namely immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have revolutionized the treatment algorithm for MM but have not yet resulted in a cure. To achieve long-lasting disease control in MM, high-dose conditioning regimen followed by ASCT continues to be an essential part of the management of transplant-eligible patients with MM. Read More

View Article and Full-Text PDF

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study.

Eur J Haematol 2022 Jun 24. Epub 2022 Jun 24.

Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.

Objective: We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma.

Methods: We retro-prospective analyzed 75 patients in 3 centers in Tuscany, 48 of whom had a clinically relevant comorbidity and 50 of whom were older than 65 years, treated with a median use in the fourth line of therapy. We assessed the efficacy based on the International Myeloma Working Group criteria. Read More

View Article and Full-Text PDF

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.

Target Oncol 2022 Jun 24. Epub 2022 Jun 24.

Janssen Research & Development, Spring House, PA, USA.

Background: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.

Objective: A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evaluating teclistamab in patients with relapsed/refractory multiple myeloma.

Patients And Methods: To estimate the efficacious therapeutic dosing range of teclistamab, pharmacokinetic (PK) data following the first cycle doses in the low-dose cohorts in the Phase I study were modeled using a 2-compartment model and simulated to predict the doses that would have average and trough serum teclistamab concentrations in the expected therapeutic range (between EC and EC values from an ex vivo cytotoxicity assay). Read More

View Article and Full-Text PDF

GPRC5D-Directed CAR Yields 100% Response Rate.


Cancer Discov 2022 Jun 24:OF1. Epub 2022 Jun 24.

Patients with refractory or relapsed multiple myeloma usually develop resistance to the two approved BCMA-targeting chimeric antigen receptor (CAR) T cells. A preliminary study of a new CAR T-cell therapy that zeroes in on the GPRC5D protein on multiple myeloma cells suggests that this approach is safe and effective. All 10 patients treated with the GPRC5D-targeting cells showed responses. Read More

View Article and Full-Text PDF

[A Case of Bladder Plasmacytoma Diagnosed during Treatment of Multiple Myeloma].

Hinyokika Kiyo 2022 May;68(5):149-153

The Department of Urology, Kobe City Nishi-Kobe Medical Center.

A 78-year-old man was treated with Bortezomib, Lenalidomide, and Dexamethasone, for multiple myeloma. Two years after the start of treatment, the patient came to our department with a complaint of gross hematuria. Cystoscopy revealed a tumor on the left wall of the bladder. Read More

View Article and Full-Text PDF

Chemo-Phototherapy with Carfilzomib-Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis.

Small 2022 Jun 24:e2200522. Epub 2022 Jun 24.

Shaanxi Key Laboratory for Advanced Energy Devices, Shaanxi Engineering Lab for Advanced Energy Technology, School of Materials Science and Engineering, Shaanxi Normal University, Xi'an, 710119, China.

The design of nanomedicine for cancer therapy, especially the treatment of tumor metastasis has received great attention. Proteasome inhibition is accepted as a new strategy for cancer therapy. Despite being a big breakthrough in multiple myeloma therapy, carfilzomib (CFZ), a second-in-class proteasome inhibitor is still unsatisfactory for solid tumor and metastasis therapy. Read More

View Article and Full-Text PDF

Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients.

Indian J Hematol Blood Transfus 2022 Jul 13;38(3):454-463. Epub 2021 Jul 13.

Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.

Multiple myeloma is the plasma cell malignancy in which bone involvement is common. The Fibroblast growth factor-23 (FGF-23)/Klotho pathway plays a major role in mineral metabolism that FGF-23 is mineralization inhibitory. Klotho also has anti-apoptotic and anti-tumor effects by acting as a tumor suppressor gene. Read More

View Article and Full-Text PDF

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis.

Transplant Direct 2022 Jul 17;8(7):e1323. Epub 2022 Jun 17.

French National Referral Centre for Cardiac Amyloidosis, Créteil, France.

Heart transplantation in cardiac amyloidosis (CA) patients is possible and generally considered for transplantation if other organs are not affected. In this study, we aimed to describe and assess outcome in patients following heart transplantations at our CA referral center.

Methods: We assessed all CA patients that had heart transplantations at our center between 2005 and 2018. Read More

View Article and Full-Text PDF